OBJECTIVES: Medication adherence and satisfaction with treatment are key dimensions of healthcare quality. Large proportion of patients with type 2 diabetes mellitus (T2DM) receive oral combination therapy. We aimed to assess medication adherence and treatment satisfaction in T2DM patients receiving oral combination therapy in a real-world setting. METHODS: RESULTS: As a whole, 90% patients had good adherence with treatment; 50% in cohort 1 vs 36% in cohort 2 were completely adhered with medication. Treatment satisfaction was high-rated by the patients; there were no patients who were extremely dissatisfied with treatment. All aspects of treatment satisfaction – overall treatment satisfaction (0.82 vs 0.54), treatment efficacy (0.98 vs 0.58), treatment convenience (0.8 vs 0.54) and coping with hypoglycemia (1.06 vs 0.63) were significantly lower in cohort 2 as compared to cohort 1 (p<0.02). In addition, 59% patients in cohort 2 experienced hypoglycemia vs 28% from those in cohort 1. The proportion of patients with better coping with hypoglycemia was higher in cohort 1 than in cohort 2 (53.7% vs 31.2; p<0.006).  CONCLUSIONS: In general, good levels of medication adherence and treatment satisfaction in T2DM patients receiving oral combination therapy were demonstrated in a real-world setting. Combination of vildagliptin plus metformin was more preferable from patients’ perspective in terms of medication adherence and treatment satisfaction as compared to SU plus metformin.